VELA Investment Management LLC Raises Position in Bruker Corporation $BRKR

Key Points

• VELA Investment Management raised its stake in Bruker by 51.0% to 102,700 shares (worth ~$4.84M), making BRKR about 1.1% of VELA's portfolio and its 20th largest holding.
• Large institutional moves continued: Goldman Sachs more than doubled its position (+107.3%) to 1,465,319 shares (~$61.16M); overall institutional ownership is 79.52% while corporate insiders hold 27.20% (VP Mark Munch sold 2,000 shares).
• On fundamentals, Bruker missed quarterly EPS ($0.59 vs. $0.65 consensus) but topped revenue estimates ($977.2M), set FY2026 guidance of 2.10–2.15 EPS (consensus ~2.12), and carries a MarketBeat consensus target of $49.38 with an average rating of "Hold."

VELA Investment Management LLC raised its holdings in Bruker Corporation (NASDAQ:BRKR - Free Report) by 51.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 102,700 shares of the medical research company's stock after buying an additional 34,700 shares during the period. Bruker makes up approximately 1.1% of VELA Investment Management LLC's portfolio, making the stock its 20th largest position. VELA Investment Management LLC owned 0.07% of Bruker worth $4,838,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of BRKR. Royal Bank of Canada lifted its position in shares of Bruker by 8.3% during the 1st quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company's stock worth $5,148,000 after purchasing an additional 9,501 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Bruker during the 1st quarter worth $262,000. Goldman Sachs Group Inc. lifted its position in shares of Bruker by 107.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company's stock worth $61,162,000 after purchasing an additional 758,301 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Bruker by 2.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company's stock worth $15,285,000 after purchasing an additional 9,235 shares during the last quarter. Finally, Focus Partners Wealth lifted its position in shares of Bruker by 115.0% during the 1st quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company's stock worth $469,000 after purchasing an additional 6,008 shares during the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Bruker news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total value of $79,800.00. Following the transaction, the vice president directly owned 128,443 shares in the company, valued at approximately $5,124,875.70. The trade was a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 27.20% of the company's stock.

Bruker Trading Up 0.2%

NASDAQ BRKR opened at $36.79 on Friday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.87 and a current ratio of 1.73. The firm has a market cap of $5.60 billion, a PE ratio of -245.27, a P/E/G ratio of 2.20 and a beta of 1.12. Bruker Corporation has a one year low of $28.53 and a one year high of $56.22. The firm's fifty day moving average is $37.13 and its two-hundred day moving average is $41.93.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings data on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing analysts' consensus estimates of $0.65 by ($0.06). The business had revenue of $977.20 million during the quarter, compared to analyst estimates of $964.61 million. Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The company's revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.76 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Analysts expect that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd were paid a $0.05 dividend. The ex-dividend date was Monday, March 23rd. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. Bruker's payout ratio is currently -133.33%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Weiss Ratings raised shares of Bruker from a "sell (d)" rating to a "sell (d+)" rating in a research report on Friday, April 24th. Jefferies Financial Group set a $50.00 price objective on shares of Bruker in a research report on Thursday, February 12th. Barclays decreased their price objective on shares of Bruker from $50.00 to $45.00 and set an "overweight" rating for the company in a research report on Tuesday, April 14th. The Goldman Sachs Group reduced their price target on shares of Bruker from $40.00 to $35.00 and set a "sell" rating for the company in a research report on Friday, February 13th. Finally, TD Cowen raised shares of Bruker to a "hold" rating in a research report on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $49.38.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.